Albumin for end-stage liver disease

Area of Science:

• Hepatology
• Nephrology
• Critical Care Medicine

Background:

• Albumin is frequently administered to patients with cirrhosis to support circulatory and renal functions.
• Established benefits include preventing renal function decline during large-volume paracentesis, spontaneous bacterial peritonitis, and hepatorenal syndrome.
• However, the evidence base varies, with some indications lacking robust randomized trial support.

Purpose of the Study:

• To review the established and controversial uses of albumin in patients with cirrhosis.
• To highlight the need for further research to define optimal albumin administration strategies.
• To explore novel applications of albumin beyond its oncotic properties.

Main Methods:

• Literature review of randomized controlled trials and clinical experience regarding albumin use in cirrhosis.
• Discussion of current controversies, including cost, lack of survival benefit, and safety concerns.
• Examination of emerging albumin-based therapies, such as albumin dialysis.

Main Results:

• Albumin infusion benefits are well-documented for specific conditions like paracentesis-induced circulatory dysfunction and hepatorenal syndrome.
• Evidence for other indications is less robust, relying on clinical experience rather than prospective studies.
• The high cost and potential risks contribute to the ongoing debate surrounding albumin's utility.

Conclusions:

• While albumin has proven benefits in select cirrhosis complications, its overall use is debated due to evidence gaps and cost-effectiveness concerns.
• Novel albumin-based therapies demonstrate its potential beyond oncotic effects.
• Further research is crucial to establish clear indications, optimal dosing, and predictive markers for albumin therapy in cirrhosis.